Boehringer Ingelheim is thinking in blockbuster terms as it throws its hat into the ever-widening CD47 ring
Boehringer Ingelheim is jumping onto the CD47 “don’t-eat-me” pathway.
The German company is paying $37 million in cash and near-term milestones to grab rights to one of the prime targets in the interplay between CD47 and SIRP-alpha. By targeting SIRP-alpha and preventing CD47 from binding to it, investigators at Boehringer believe that they can defuse a key immunosuppressant and allow macrophages to go on a cancer cell rampage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.